IP Library Granted Patent US 10,758,333
Granted Patent B2
US 10,758,333 · App. 15/714,868 · Granted Sep 1, 2020

High resistance implanted bronchial isolation devices and methods

Inventors: Sri Radhakrishnan (Cupertino, CA); Ryan Olivera (Granite Bay, CA)
Assignee: Pulmonx Corporation
A61F2/04A61B17/12036A61B17/12104A61B17/12172A61M16/0406A61M16/209A61B17/12177A61F2002/043A61M16/208A61M2205/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,333
App. No.
15/714,868
Granted
Sep 1, 2020
Kind
B2
Abstract

Disclosed are methods and devices for regulating fluid flow to and from a region of a patient's lung, such as to achieve a desired fluid flow dynamic to a lung region during respiration and/or to induce collapse in one or more lung regions. Pursuant to an exemplary procedure, an identified region of the lung is targeted for treatment. The targeted lung region is then bronchially isolated to regulate airflow into and/or out of the targeted lung region through one or more bronchial passageways that feed air to the targeted lung region. An exemplary flow control device is configured to block fluid flow in the inspiratory direction and the expiratory direction at normal breathing pressures and allow fluid flow in the expiratory direction at coughing pressures.

Claims (17)

1. A flow control device suitable for implanting in a bronchial passageway, comprising:

a valve element comprising a first lip, a second lip, and two opposed inclined flaps leading to the first and second lips, wherein the first and second lips are configured to transition the valve element between a closed configuration that blocks air flow in the inspiratory direction and an open configuration that permits air flow in an expiratory direction, wherein the first and second lips are configured to be parallel with respect to one another and a longitudinal axis of the valve and extend longitudinally in contact with one another beyond the two inclined flaps while in the closed configuration, and wherein the two inclined flaps are configured to be oriented at an angle with respect to one another in the closed configuration;

wherein a length of the parallel and contacted first and second lips extending longitudinally beyond the two inclined flaps and the angle of the inclined flaps with respect to one another are configured such that the valve element is in the closed configuration when exposed to no air flow, air flow in the inspiratory direction, and air flow in the expiratory direction at normal breathing pressures, and such that the valve element is in the open configuration when exposed to air flow in the expiratory direction at coughing pressures;

wherein the valve is configured to have a cracking pressure in the range of 12-24 inches H 2 O.

2. The flow control device of claim 1 , wherein the angle is in the range of 70 to 110 degrees.

3. The flow control device of claim 1 , wherein the two inclined flaps are oriented at an angle relative to a longitudinal axis of the valve while in the closed configuration.

4. The flow control device of claim 1 , further comprising a frame configured to retain the flow control device within the bronchial passageway; and a seal coupled to the frame, the seal configured to seal against internal walls of the bronchial passageway.

5. A flow control device suitable for implanting in a bronchial passageway, comprising:

a valve comprising coaptation regions comprising two opposed straight inclined flaps and two parallel lips connected to the straight inclined flaps, wherein the coaptation regions are configured to transition the valve element between a closed configuration that blocks air flow in the inspiratory direction and an open configuration that permits air flow in an expiratory direction, wherein the two opposed straight inclined flaps are configured to be oriented at an angle with respect to one another in the closed configuration, and the two parallel lips are configured to be parallel with respect to one another and a longitudinal axis of the valve and extend longitudinally in contact with one another beyond the two straight inclined flaps while in the closed configuration;

wherein a length of the parallel and contacted parallel lips extending longitudinally beyond the two straight inclined flaps and the angle of the straight inclined flaps with respect to one another are configured such that the coaptation regions are in the closed configuration when exposed to no air flow, air flow in the inspiratory direction, and air flow in the expiratory direction at normal breathing pressures, and such that the coaptation regions are in the open configuration when exposed to air flow in the expiratory direction at coughing pressures;

wherein the valve is configured to have a cracking pressure in the range of 12-24 inches H 2 O.

6. The flow control device of claim 5 , wherein the two opposed inclined flaps are configured to be oriented at an angle with respect to a longitudinal axis of the valve in the closed configuration.

7. The flow control device of claim 5 , wherein the valve is configured to have a cracking pressure in the range of 15-24 inches H 2 O.

8. The flow control device of claim 1 , wherein the valve is configured to have a cracking pressure in the range of 15-24 inches H 2 O.

9. The flow control device of claim 5 , further comprising a frame configured to retain the flow control device within the bronchial passageway; and a seal coupled to the frame, the seal configured to seal against internal walls of the bronchial passageway.

10. The flow control device of claim 1 , wherein the a valve element is configured to be oriented at an angle with respect to a direction of air flow through the bronchial passageway.

11. The flow control device of claim 5 , wherein the a valve is configured to be oriented at an angle with respect to a direction of air flow through the bronchial passageway.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: PULMONX CORPORATION
Reel/Frame 075028/0274 →
SECURITY INTEREST Recorded Mar 2, 2026
From: PULMONX CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 075012/0453 →
SECURITY INTEREST Recorded Jan 27, 2026
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 074570/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: RADHAKRISHNAN, SRI; OLIVERA, RYAN
To: PULMONX CORPORATION
Reel/Frame 052592/0850 →
SECURITY INTEREST Recorded Mar 2, 2020
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 052916/0213 →